biosimilar infliximab on the up as French hospitals secure steep discount
This article was originally published in Scrip
Executive Summary
Predictions that biosimilar versions of infliximab will continue to erode the European market share of Merck/J&J's Remicade appear to be holding up after it was announced that the Paris hospital group AP-HP has agreed a 45% discount on the cost of Hospira's Inflectra versus Remicade.